Browse Conditions Browse Medicines

NICE launch evidence review on Impetigo: antimicrobial prescribing guideline

For Impetigo

The National Institute for Health and Care Excellence (NICE) have launched a consultation for an evidence review on Impetigo: antimicrobial prescribing guideline.

The consultation is open until 11 September 2019 at 5 p.m.

The guideline sets out an antimicrobial prescribing strategy for impetigo. It aims to optimise antibiotic use and reduce antibiotic resistance. The recommendations in this guideline are for the use of antiseptics and antibiotics to manage impetigo in adults, young people and children. It does not cover diagnosis.

Please note that the scope of this guideline is for adults, young people and children aged 72 hours and over. For treatment of children in the first 72 hours of life, please seek specialist advice.

Who is it for?
  • Adults, young people and children with impetigo, their parents and carers
  • Healthcare professionals
The guideline contains:
  • the draft recommendations
  • the rationales
  • summary of the evidence

About impetigo (source NHS)
Impetigo is a skin infection that's very contagious but not usually serious. It often gets better in 7 to 10 days if you get treatment. Anyone can get it, but it's very common in young children.

Impetigo starts with red sores or blisters. They quickly burst and leave crusty, golden-brown patches.

These can:
  • look a bit like cornflakes stuck to your skin
  • get bigger
  • spread to other parts of your body
  • be itchy
  • sometimes be painful
A GP will check it's not something more serious, like cellulitis.

If it's impetigo, they can prescribe antibiotic cream to speed up your recovery or antibiotic tablets if it's very bad.

NHS website for impetigo
Contains public sector information licensed under the Open Government Licence v3.0.
Accessed 16/08/19
Links available in External Resources

© NICE [2019]

Impetigo: antimicrobial prescribing. In development [GID-NG10134]. Expected publication date: 14 February 2020
Available from: See Link below. All rights reserved. Subject to Notice of rights
NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

The information provided by NICE was accurate at the time this article was issued.

NICE information on impetigo evidence review

Reporting of suspected adverse reactions

Reporting suspected adverse reactions (side effects) after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals or patients are asked to report any suspected adverse reactions via the Yellow Card Scheme at or search for MHRA Yellow Card in the Google Play or Apple App Store.

Disclaimer: This site is designed to offer information for general educational purposes only. The health information furnished on this site and the interactive responses are not intended to be professional advice and are not intended to replace personal consultation with a qualified physician, pharmacist, or other healthcare professional. We cannot provide individual medical advice. You must always seek the advice of a professional for questions related to a disease, disease symptoms, and appropriate therapeutic treatments.

About condition